Invasive Fungal Disease
Conditions
Brief summary
Efficacy and safety of amphotericin B and azoles in the treatment of invasive fungal disease
Detailed description
The medical records, demographic characteristics and clinical data of patients with invasive fungal disease treated with amphotericin B or azoles were collected through the electronic medical record system of Sichuan Provincial People's Hospital from 2021 to 2024. To evaluate the efficacy and safety of these two types of drugs.
Interventions
None listed
Sponsors
Sichuan Provincial People's Hospital
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* There is no age limit, gender is not limited * Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for ≥ 7 days.
Exclusion criteria
* Patients with incomplete data or other factors affecting the clinical outcome judgement * Patients who are judged by the investigator to be unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical success rate | The end of treatment, up to 1 year | Clinical success incudes cure or symptom improvement，which means patients are alive, IFD-related symptoms and signs, radiographic abnormalities improve or disappear completely, and microbiological evidence suggests fungal clearance. The proportion of patients with cured or improved symptoms in the total population was analyzed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety of amphotericin B and azoles | During the treatment (1-14 days); the end of treatment (Day 14);Day 28 after the start of treatment | Safety evaluation was mainly based on the incidence of adverse events / adverse reactions in the two groups of patients. |
Countries
China
Contacts
Primary Contactlingai Pan, PhD
Outcome results
None listed